Journal News

Innovative platform empowers scientists to transform venoms into therapeutics

Andrea Lius
May 13, 2025

Some of the most successful and effective drugs, like Ozempic, come from animal venoms. However, scientists usually only discover the therapeutic potential of venoms by chance. Recently, an international group of researchers, led by Meng-Hsuan Hsiao of Ben Larman ’s laboratory at Johns Hopkins University, set out to change that by developing a workflow to accelerate drug discovery from peptides, or short sequences of amino acids, with sequences and structures that resemble animal venoms. They published their study in Molecular & Cellular Proteomics.

Simplified diagram of Meng-Hsuan Hsiao of Ben Larman’s platform to facilitate drug discovery from animal venoms using M13 hyperphages.
Ben Larman
Simplified diagram of Meng-Hsuan Hsiao of Ben Larman’s platform to facilitate drug discovery from animal venoms using M13 hyperphages.

Hsiao and colleagues demonstrated that their platform could evaluate over 10,000 venom-like peptides’ ability to bind specific receptors on human cells. Larman’s group teamed up with Martin Steinegger, an assistant professor at Seoul National University, who built a “metavenome library” from known animal venom sequences and additional peptides based on sequence homology.

“A library allows us to explore a much larger space of possible lead compounds for drugs,” Larman said. “You don’t even need to have a starting hypothesis.”

The researchers expressed peptides from this library on the surface of bacteriophages, or bacteria-infecting viruses, a technique also known as phage display. For their platform, Larman’s team used what he called a specific “flavor” of phage: the M13 hyperphage.

Hyperphages carry genetic mutations that make them display five copies of venom-like peptides on their surface. Therefore, the displayed peptides could interact with multiple receptors, amplifying the signal and allowing the researchers to detect weaker interactions.

“The way we used hyperphages to display venoms has never been done before,” said Larman.

Unlike other phages, M13 phages are secreted through the bacterial periplasm, the space between the bacteria’s inner and outer cell membranes. The periplasm has an oxidizing chemical environment, Larman explained, and this helps preserve the venom peptides’ disulfide bonds, which are critical for their 3D structures. These disulfide bonds make venoms attractive therapeutics because they are highly compact and resistant to degradation.

Using their platform, Larman’s team identified six proteins in the metavenome library that bind and activate the human itch receptor MAS-related G protein-coupled receptor X4, or MRGPRX4. They found that these proteins share a unique folding pattern called the Kunitz domain, which is commonly known to inhibit serine protease activity. In the future, Larman’s team plans to expand their metavenome library to include even more peptides in search of a potent MRGPRX4 antagonist that can be developed into an anti-itch drug.

“I think that if you can find an agonist, you can also find an antagonist,” Larman said, “And we can likely achieve this by expanding our library.”

Larman said he hopes to integrate generative artificial intelligence into their system to broaden the library to include novel venom-like peptides.

“Once set up and integrated,” he said. “I can see this cycle of computational prediction and experimental validation being really powerful in drug discovery.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Andrea Lius

Andrea Lius is a Ph.D. candidate in the Ong quantitative biology lab at the University of Washington. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Neurobiology of stress and substance use
Profile

Neurobiology of stress and substance use

June 19, 2025

MOSAIC scholar and proud Latino, Bryan Cruz of Scripps Research Institute studies the neurochemical origins of PTSD-related alcohol use using a multidisciplinary approach.

Pesticide disrupts neuronal potentiation
Journal News

Pesticide disrupts neuronal potentiation

June 17, 2025

New research reveals how deltamethrin may disrupt brain development by altering the protein cargo of brain-derived extracellular vesicles. Read more about this recent Molecular & Cellular Proteomics article.

A look into the rice glycoproteome
Journal News

A look into the rice glycoproteome

June 17, 2025

Researchers mapped posttranslational modifications in Oryza sativa, revealing hundreds of alterations tied to key plant processes. Read more about this recent Molecular & Cellular Proteomics paper.

Proteomic variation in heart tissues
Journal News

Proteomic variation in heart tissues

June 17, 2025

By tracking protein changes in stem cell–derived heart cells, researchers from Cedars-Sinai uncovered surprising diversity — including a potential new cell type — that could reshape how we study and treat heart disease.

Parsing plant pigment pathways
Webinar

Parsing plant pigment pathways

June 13, 2025

Erich Grotewold of Michigan State University, an ASBMB Breakthroughs speaker, discusses his work on the genetic regulation of flavonoid biosynthesis.

Calcium channel linked to cancer drug resistance
Journal News

Calcium channel linked to cancer drug resistance

June 12, 2025

Researchers discover a protein associated with carboplatin-resistant retinoblastoma, suggesting this protein could be a promising therapeutic target. Read more about this recent Journal of Biological Chemistry paper.